Goals of chronic obstructive pulmonary disease management: a focused review for clinicians.

IF 2.8 3区 医学 Q2 RESPIRATORY SYSTEM
Current Opinion in Pulmonary Medicine Pub Date : 2025-03-01 Epub Date: 2024-12-02 DOI:10.1097/MCP.0000000000001144
Sairam Raghavan, Umur Hatipoğlu, Loutfi S Aboussouan
{"title":"Goals of chronic obstructive pulmonary disease management: a focused review for clinicians.","authors":"Sairam Raghavan, Umur Hatipoğlu, Loutfi S Aboussouan","doi":"10.1097/MCP.0000000000001144","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>The diagnosis of chronic obstructive pulmonary disease (COPD) encompasses heterogeneous pathophysiological mechanisms which can shape an individual patient's experience. This paper reviews available therapeutic options for the clinician intending to individualize care toward patient goals.</p><p><strong>Recent findings: </strong>The contemporary targeted interventions for COPD include the novel phosphodiesterase inhibitor ensifentrine, the interleukin-4 receptor (IL4R alpha subunit) antibody dupilumab, augmentation therapy for alpha-1 antitrypsin deficiency. Other interventions promoting physical and mental well being include re-envisioned pulmonary rehabilitation, self-management, targeting of comorbidities such as sarcopenia, and virtual health coaching interventions to expand patient access. Opioids did not relieve dyspnea and did not change total step count.</p><p><strong>Summary: </strong>Advances in precision therapy are complemented by the discovery of novel pathophysiology pathways and behavioral and rehabilitation interventions as a holistic view of COPD management emerges. The management of COPD continues to evolve with new tools including precision medicine and individualized care. Comorbidities remain important determinants of health, yet their prevalence and impact are underestimated.</p>","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"156-164"},"PeriodicalIF":2.8000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Pulmonary Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MCP.0000000000001144","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/2 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose of review: The diagnosis of chronic obstructive pulmonary disease (COPD) encompasses heterogeneous pathophysiological mechanisms which can shape an individual patient's experience. This paper reviews available therapeutic options for the clinician intending to individualize care toward patient goals.

Recent findings: The contemporary targeted interventions for COPD include the novel phosphodiesterase inhibitor ensifentrine, the interleukin-4 receptor (IL4R alpha subunit) antibody dupilumab, augmentation therapy for alpha-1 antitrypsin deficiency. Other interventions promoting physical and mental well being include re-envisioned pulmonary rehabilitation, self-management, targeting of comorbidities such as sarcopenia, and virtual health coaching interventions to expand patient access. Opioids did not relieve dyspnea and did not change total step count.

Summary: Advances in precision therapy are complemented by the discovery of novel pathophysiology pathways and behavioral and rehabilitation interventions as a holistic view of COPD management emerges. The management of COPD continues to evolve with new tools including precision medicine and individualized care. Comorbidities remain important determinants of health, yet their prevalence and impact are underestimated.

慢性阻塞性肺疾病管理的目标:临床医生的重点综述。
综述的目的:慢性阻塞性肺疾病(COPD)的诊断包含不同的病理生理机制,这些机制可以塑造个体患者的经历。本文回顾了现有的治疗方案,为临床医生打算个性化护理病人的目标。近期发现:当前针对COPD的靶向干预包括新型磷酸二酯酶抑制剂ensifentrine,白细胞介素-4受体(IL4R α亚基)抗体dupilumab, α -1抗胰蛋白酶缺乏症的强化治疗。其他促进身心健康的干预措施包括重新设想肺部康复、自我管理、针对肌肉减少症等合并症以及扩大患者可及性的虚拟健康指导干预措施。阿片类药物没有缓解呼吸困难,也没有改变总步数。总结:随着COPD治疗的整体观点的出现,新的病理生理途径以及行为和康复干预的发现补充了精准治疗的进步。随着包括精准医疗和个体化护理在内的新工具的出现,慢性阻塞性肺病的管理不断发展。合并症仍然是健康的重要决定因素,但其流行程度和影响被低估了。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
109
审稿时长
6-12 weeks
期刊介绍: ​​​​​​Current Opinion in Pulmonary Medicine is a highly regarded journal offering insightful editorials and on-the-mark invited reviews, covering key subjects such as asthma; cystic fibrosis; infectious diseases; diseases of the pleura; and sleep and respiratory neurobiology. Published bimonthly, each issue of Current Opinion in Pulmonary Medicine introduces world renowned guest editors and internationally recognized academics within the pulmonary field, delivering a widespread selection of expert assessments on the latest developments from the most recent literature.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信